DKSH Accelerates: Data Center, Healthcare Deals, and AI Investments Drive H1 Growth
Net sales +4.9%, EPS +10.6% in H1 2026, with strong cash conversion and a margin dip from FX and ramp-up costs.
DKSH.SW · Earnings Call · 2026-07-17
A Return to Double-Digit EPS Growth
DKSH's half-year 2026 results mark a meaningful acceleration. Net sales grew 4.9% to CHF 5.5 billion in constant FX — the strongest first-half print in three years — while earnings per share jumped 10.6% to CHF 1.56. “Net sales increased by 4.9% to CHF 5.5 billion. This is the strongest first half revenue growth we have achieved in three years.” — Stefan Butz, Chief Executive Officer · 2026-07-17 The growth is broad-based, but the standout story is the combination of business development wins and a structural shift into higher-margin services, particularly in Healthcare and Technology.Healthcare: A Pipeline of Big Deals
Healthcare, the largest business unit, grew net sales 4.9% to CHF 2.9 billion and continues to sign material contracts. The newly disclosed Lilly partnership in Hong Kong is the largest in company history. “We recently signed our largest deal with Lilly in Hong Kong, which we expect to generate over 100 million sales contribution per year.” — Stefan Butz, Chief Executive Officer · 2026-07-17 The management team expects these wins to accelerate healthcare growth by roughly 2 percentage points per year over the medium term, even as they temporarily pressure margins due to ramp-up investments. The margin dip is, in Stefan Butz's words, "a very good investment for the future."Technology: Riding the Data Center Wave
The Technology business unit is a clear beneficiary of the global data center boom. Core EBIT surged 90% to CHF 13.4 million, lifting its margin from 3.1% to 5.6%. “We benefited from increased demand in the data center business, where we provide the supply, installation, and servicing of backup power solutions.” — Stefan Butz, Chief Executive Officer · 2026-07-17 This aligns with a broader tape trend where data-center-related keywords like "data center AI" and "co packaged optics" are posting strong price returns. DKSH is leveraging its distribution and after-sales network to capture this demand, and the pipeline remains robust.AI and M&A: Fuel for the Next Phase
Beyond the topline, DKSH is investing heavily in AI capabilities — from an internal AI team of 16 specialists to tools like Polaris for sales optimization and automated order management. These investments are part of the reason the group's Core EBIT margin dipped 10 bps to 3.0%, but management expects them to pay off via productivity gains and new revenue streams. At the same time, M&A activity has accelerated: 12 acquisitions announced since the start of 2025, including three in the first half alone. The company's cash conversion remains exceptional at 130.8% (well above the 90% target), giving it ample firepower for further deals. The margin outlook is a key watchpoint. CFO Ido Wallach noted that FX translation headwinds should subside in the second half, while the ramp-up costs in Healthcare will persist into 2027. Still, management is confident it can deliver a modest margin expansion for the full year.In summary, DKSH is executing a clear strategy: accelerate growth via high-value contracts in Healthcare, capture the data center tailwind in Technology, and use AI and M&A to widen margins over the long term. The first half of 2026 shows that this plan is gaining traction.Clearly, I do not foresee, as you were provoking, in 2027, a flat margin. That margin will continue to grow over the years to come.